3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
3
Leukemia
3
Vomiting
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Motor Activity
2
Ventilator-Induced Lung Injury
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Substance-Related Disorders
1
Solid Tumors
1
Recurrence
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Opioid-Related Disorders
1
Opioid-Induced Constipation
1
Neurofibromatosis 1
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Low Anterior Resection Syndrome
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
aldesleukin
42
Sunitinib
39
Cyclophosphamide
30
Nivolumab
27
Everolimus
27
pembrolizumab
26
Interferon-alpha
25
Bevacizumab
22
Sorafenib
21
Interleukin-2
20
fludarabine phosphate
19
Filgrastim
18
Ipilimumab
17
Radiotherapy
16
Axitinib
16
Peripheral Blood Stem Cell Transplantation
15
Gemcitabine
15
cabozantinib
14
fludarabine
11
Radiosurgery
11
Doxorubicin
11
Carboplatin
11
temsirolimus
10
Etoposide
9
Chemotherapy, Adjuvant
9
sargramostim
8
belzutifan
8
atezolizumab
8
Fluorouracil
8
pazopanib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Kidney Neoplasms
×
Dosage Forms
×
Clear all
NCT04644432
2020-11-25
INDIGO
Herlev and Gentofte Hospital
Phase 2
Unknown
30 enrolled